Ask AI
ProCE Banner Activity

Insights from HOPA 2025: Incorporating Bispecific Antibodies Into NHL Management

Clinical Thought

Bispecific antibodies are important options for treating relapsed/refractory NHL in both community and academic practice settings. We discuss strategies for incorporating bispecific antibodies into clinical practice and approaches to mitigate treatment-related adverse events to individualize and optimize therapy.

Released: June 26, 2025

Expiration: June 25, 2026

Share

Provided by

Provided by ProCE, LLC, in partnership with Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Genentech, a member of the Roche Group.

Genentech, a member of the Roche Group

Partners

Clinical Care Options, LLC

ProCE Banner

Faculty Disclosure

Primary Author

C. Brooke Adams, PharmD, BCOP: consultant/advisor/speaker: Genmab, Johnson & Johnson, Pfizer.

Sarah Profitt, PharmD, BCOP: consultant/advisor/speaker: Blueprint Medicines, Genentech, Lilly, Rigel.